Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity Terminated Phase 1 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0028768 (Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00906360Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckTreatment